Detail akcie Molecular Partn N online

Business Summary: Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Molecular Partners AG revenues was not reported. Net loss applicable to common stockholders decreased 22% to SF13.1M. Lower net loss reflects Research and development expenses decrease of 21% to SF9.4M (expense), Net foreign exchange loss decrease from SF1.1M (expense) to SF0K, Selling/General/Admin Expense decrease of 5% to SF4M (expense).